Evidence map›Paper›PMID 39715683›Full record

ArticleGenome research2025

Aberrant homeodomain-DNA cooperative dimerization underlies distinct developmental defects in two dominant

Yiqiao Zheng, Gary D Stormo, Shiming Chen

Abstract read
In one paragraph

Article in Genome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. PreclinicalbioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Yiqiao ZhengMolecular Genetics and Genomics Graduate Program, Division of Biology & Biomedical Sciences, Washington University in St. Louis, St. Louis, Missouri 63110, USA.ORCID 0000-0003-4133-0439
Gary D StormoDepartment of Genetics, Washington University in St Louis, Saint Louis, Missouri 63110, USA; chenshiming@wustl.edu stormo@wustl.edu.ORCID 0000-0001-6896-1850
Shiming ChenDepartment of Ophthalmology and Visual Sciences, Washington University in St Louis, Saint Louis, Missouri 63110, USA; chenshiming@wustl.edu stormo@wustl.edu.ORCID 0000-0002-9299-5767

Funding

WASHINGTON UNIVERSITY CENTER VISION RESEARCHP30EY002687 · NEI · WASHINGTON UNIVERSITY · PI Steven Bassnett · 1985 to 2026
$18.4M
Vulnerable and Resilient Cells in Retinal DegenerationR01EY012543 · NEI · WASHINGTON UNIVERSITY · PI SHIMING CHEN, Philip Raymond Williams · 2000 to 2026
$12.2M
Understanding and treating CRX-linked retinopathiesR01EY032136 · NEI · WASHINGTON UNIVERSITY · PI CHEN, SHIMING · 2021 to 2025
$1.9M
CIS-REGULATORY MECHANISMS UNDERLYING RETINOPATHYR01EY027784 · NEI · WASHINGTON UNIVERSITY · PI CHEN, SHIMING, COHEN, BARAK A · 2017 to 2020
$1.4M
NEI NIH HHS P30 EY002687NEI NIH HHS R01 EY012543NEI NIH HHS R01 EY027784NEI NIH HHS R01 EY032136
6 · The paper itself

Abstract

Paired-class homeodomain (HD) transcription factors (TFs) play essential roles in vertebrate development, and their mutations are linked to human diseases. One unique feature of a paired-class HD is cooperative dimerization on specific palindrome DNA sequences. Yet, the functional significance of HD cooperative dimerization in animal development and its dysregulation in diseases remains elusive. Using the retinal TF cone-rod homeobox (CRX) as a model, we have studied how blindness-causing mutations in the paired HD, p.E80A and p.K88N, alter CRX's cooperative dimerization, leading to gene misexpression and photoreceptor developmental deficits in dominant manners. CRX

Indexed as

DNAHomeodomain ProteinsRetinal DiseasesTrans-ActivatorsAnimalsDisease Models, AnimalHumansMiceMutationProtein MultimerizationRetinacone rod homeobox proteinDNAHomeodomain ProteinsTrans-Activators

Identifiers

PMID39715683
PMCPMC11874979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.